Citation

Niewoehner CB, Niewoehner DE. Postgrad. Med. 1999; 105(3): 79-83, 87-8, 91.

Affiliation

Division of Endocrinology, Metabolism, and Nutrition, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA. niewo002@maroon.tc.umn.edu

Copyright

(Copyright © 1999, Vendome Group)

DOI

unavailable

PMID

10086035

Abstract

Asthmatic patients who rely on long-term, high-dose corticosteroid therapy are at increased risk for osteoporosis. The use of low-dose inhaled corticosteroids may be safe enough not to require special assessment of bone loss or preventive measures. However, evidence is lacking on the risks of long-term use of higher doses. Regardless of dose, all patients given long-term systemic corticosteroids should be carefully examined and, if necessary, treated for bone loss.

Language: en